OKYO Pharma (OKYO) director buys 5,000 shares in open market
Rhea-AI Filing Summary
OKYO Pharma Ltd director John P. Brancaccio reported an open-market purchase of 5,000 shares of common stock on July 21, 2026 at $1.477 per share. Following this trade, he directly owns 35,201 shares.
The amended insider report corrects the transaction code for this purchase and indicates the trade was not made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
BRANCACCIO JOHN P
Role
Director
Bought
5,000 shs ($7K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 5,000 | $1.477 | $7K |
Holdings After Transaction:
COMMON STOCK — 35,201 shares (Direct)
Key Figures
Shares purchased: 5,000 shares
Purchase price: $1.477 per share
Shares owned after transaction: 35,201 shares
+1 more
4 metrics
Shares purchased
5,000 shares
Common stock bought on July 21, 2026
Purchase price
$1.477 per share
Open-market transaction price
Shares owned after transaction
35,201 shares
Direct ownership following the reported purchase
Net buy shares
5,000 shares
Net buy-sell volume reported in this insider transaction
Key Terms
Form 4/A, open market purchase, non-derivative
3 terms
Form 4/A regulatory
"This Form 4/A amends the Form 4 filed on July 23, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
open market purchase financial
"correct the transaction code associated with this open market purchase"
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
non-derivative financial
""transaction_type": "non-derivative""
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider purchase did OKYO (OKYO) director John P. Brancaccio report?
He reported an open-market purchase of 5,000 OKYO Pharma common shares on July 21, 2026 at $1.477 per share. After this transaction, his directly held position increased to 35,201 shares, based on the amended insider ownership disclosure.
When did the OKYO (OKYO) insider transaction occur and at what price?
The reported insider transaction occurred on July 21, 2026, when John P. Brancaccio bought 5,000 OKYO Pharma common shares. The shares were acquired in the open market at a price of $1.477 per share.
Why was an amended insider report filed for OKYO Pharma Ltd (OKYO)?
An amended insider report was filed solely to correct the transaction code associated with the reported open-market purchase. The amendment states that no other previously reported transactions are affected, and the economic details of the 5,000-share purchase remain unchanged.
Was the OKYO (OKYO) insider purchase made under a Rule 10b5-1 trading plan?
The transaction was not reported as made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox was left unchecked, indicating the open-market purchase of 5,000 shares was not executed pursuant to a pre-arranged trading plan.